Evobrutinib treatment improves neurological function of mice with cerebral ischemia, and alleviates neuroinflammation by inhibiting M1 microglia polarization through TLR4/Myd88/NF-κB pathway. The gene discussed is MYD88; the disease is brain ischemia.